Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 291 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Trial Suggests Expanded Role for Blinatumomab in Treating ALL January 25, 2023 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer January 11, 2021 FDA Approvals Bring New Options for Older Patients with AML December 27, 2018 Load more HOT NEWS Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer Thinking outside the box to tackle an aggressive children’s cancer New on NCI’s Websites for November 2021 Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable...
